secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001628280-24-026903
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo shareholders approve increase in authorized shares and equity plan share reserve at annual meeting
--------------------------------------------------------------------------------

- Authorized common stock increased from 640M to 960M shares (320M increase).
- 2018 Equity Incentive Plan amended to add 11M shares to the reserve (total available now ~49.3M plus returning shares).
- All nine director nominees elected; advisory 'say-on-pay' passed with 101.3M votes for vs 15.1M against.
- Ratification of Ernst & Young as independent auditor for FY2024 approved with 151.1M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/0001628280-24-026903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024026903/sgmo-20240604.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-026903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer